A guidance document finalized in June gave manufacturers more freedom to discuss devices in ways not specifically included in the labeling, but US FDA and industry are still feeling out the limits of the protection.
That was the message from two sessions at the Food & Drug Law Institute’s Advertising and Promotions Conference held this...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?